Dermata Therapeutics (DRMA) director gets 2,500 stock options grant

Rhea-AI Filing Summary

Dermata Therapeutics director Andrew Seth Sandler received a grant of stock options for 2,500 shares on January 2, 2026. The options have an exercise price of $2.18 per share and expire on January 1, 2036. They vest in twelve substantially equal monthly installments, starting one month after the grant date, contingent on his continuous service. Following this award, he beneficially owned 2,500 derivative securities directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Sandler Andrew Seth

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	2,500	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 2,500 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sandler Andrew Seth

(Last) (First) (Middle)

3525 DEL MAR HEIGHTS RD., #322

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Dermata Therapeutics, Inc. [ DRMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.18	01/02/2026		A		2,500		(1)	01/01/2036	Common Stock	2,500	$0	2,500	D

Explanation of Responses:

1. The shares underlying the option will vest in a series of twelve (12) successive substantially equal monthly installments, with the first installment vesting on the one month anniversary of the grant date and continuing to vest monthly thereafter, subject to Reporting Person's continuous service through each such vesting date.

	/s/ Gerald T. Proehl, Attorney-in-Fact	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Dermata Therapeutics (DRMA) report on this Form 4?

The filing reports that director Andrew Seth Sandler received a grant of stock options for 2,500 shares of Dermata Therapeutics common stock on January 2, 2026.

Was the Dermata Therapeutics Form 4 transaction a purchase or a stock option grant?

The transaction is coded A, indicating an award/grant of a derivative security, specifically stock options, rather than an open-market purchase or sale.

What is the exercise price and expiration date of Andrew Seth Sandlers Dermata stock options?

The stock options have an exercise price of $2.18 per share and an expiration date of January 1, 2036.

How do the Dermata Therapeutics stock options granted to Andrew Seth Sandler vest?

The 2,500 options vest in twelve substantially equal monthly installments, with the first installment vesting one month after the grant date and continuing monthly, subject to his continuous service on each vesting date.

How many Dermata Therapeutics derivative securities does Andrew Seth Sandler own after this Form 4 transaction?

After this grant, Andrew Seth Sandler beneficially owned 2,500 derivative securities (stock options) on a direct ownership basis, according to the filing.

Does this Dermata Therapeutics Form 4 indicate indirect ownership through another entity?

No. The reported stock options are listed with direct ownership, and the filing does not describe any indirect ownership through another entity.